BeiGene has reported first-half 2026 operating revenue of RMB 22.220 billion (USD 3.3 billion), up 26.8% year-on-year. Q2 standalone revenue reached RMB 11.676 billion (USD 1.7 billion), the second consecutive quarter above RMB 10 billion, prompting the company to lift its full-year revenue guidance to RMB 44.9 to 46.2 billion and its operating-cost-adjusted income band to RMB 11.5 to 12.2 billion.

Product revenue of RMB 21.797 billion (USD 3.2 billion; +25.6%) was anchored by zanubrutinib (Brukinsa) at RMB 16.127 billion (+28.7%, with RMB 11.390 billion from the US), tislelizumab at RMB 2.984 billion (+12.9%), and Amgen-partnered products at RMB 2.065 billion (+19.6%).

Zanubrutinib's breadth across CLL, WM, MCL, and MZL, reinforced by 78-month SEQUOIA data and positive MANGROVE results, underpins planned first-line MCL filings in the China, Europe, Japan and the US in late 2026.

In pipeline execution, sonrotoclax (BGB-16673-class BCL2 inhibitor) secured US accelerated approval in relapsed/refractory MCL, the BTK CDAC tacabrutideg is advancing toward a potential R/R CLL application in H2 2026, and CDK4 inhibitor, B7-H4 ADC, and GPC3×4-1BB bispecific programmes are progressing in Phase III or pivotal solid-tumour studies.

A USD 300 million expansion of a US site adds small-molecule capacity to the global supply network, rounding out a transition from single-asset dependence to multi-franchise haematology-oncology scale.